Dermatose neutrophilique aiguë induite par le bortezomib

Abstract

Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients. We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present. The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence.